Market Cap | 132.67M | P/E | - | EPS this Y | 77.10% | Ern Qtrly Grth | - |
Income | -80.85M | Forward P/E | -1.15 | EPS next Y | -163.00% | 50D Avg Chg | 3.00% |
Sales | 95.84M | PEG | -0.68 | EPS past 5Y | - | 200D Avg Chg | -56.00% |
Dividend | N/A | Price/Book | N/A | EPS next 5Y | 5.20% | 52W High Chg | -91.00% |
Recommedations | 2.00 | Quick Ratio | 7.93 | Shares Outstanding | 226.23M | 52W Low Chg | 53.00% |
Insider Own | 2.95% | ROA | -15.63% | Shares Float | 187.64M | Beta | 1.96 |
Inst Own | 81.12% | ROE | -863.39% | Shares Shorted/Prior | 8.55M/9.58M | Price | 1.39 |
Gross Margin | 100.00% | Profit Margin | -84.36% | Avg. Volume | 2,536,038 | Target Price | 6.72 |
Oper. Margin | 54.35% | Earnings Date | Nov 7 | Volume | 1,718,679 | Change | 0.00% |
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
HC Wainwright & Co. | Buy | Sep 17, 24 |
HC Wainwright & Co. | Buy | Aug 30, 24 |
Wedbush | Outperform | Aug 13, 24 |
Oppenheimer | Outperform | Jun 25, 24 |
Goldman Sachs | Buy | Jun 17, 24 |
HC Wainwright & Co. | Buy | May 20, 24 |
Wedbush | Outperform | May 8, 24 |
HC Wainwright & Co. | Buy | May 6, 24 |
Piper Sandler | Overweight | Mar 27, 24 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Giraudo Bryan | COO/CFO COO/CFO | Nov 13 | Buy | 0.5644 | 200,000 | 112,880 | 380,010 | 11/14/23 |
Christian Waage | EVP, Tech Ops and Ad.. EVP, Tech Ops and Admin | Mar 20 | Buy | 1.197 | 18,500 | 22,144 | 32,388 | 03/22/23 |
Giraudo Bryan | COO/CFO COO/CFO | Mar 20 | Buy | 0.9687 | 50,000 | 48,435 | 70,990 | 03/22/23 |
Hasnain Faheem | President & CEO President & CEO | Mar 20 | Buy | 1.12 | 878,572 | 984,001 | 4,495,897 | 03/22/23 |
Carter Laura | Chief Scientific Off.. Chief Scientific Officer | Mar 16 | Sell | 1.098 | 6,029 | 6,620 | 76,263 | 03/20/23 |
Aranda Richard | Chief Medical Office.. Chief Medical Officer | Mar 16 | Sell | 1.098 | 7,563 | 8,304 | 199,388 | 03/20/23 |
Peterson Caryn | EVP, Regulatory Affa.. EVP, Regulatory Affairs | Mar 16 | Sell | 1.098 | 7,564 | 8,305 | 53,851 | 03/20/23 |
Giraudo Bryan | COO/CFO COO/CFO | Jul 15 | Buy | 7.21 | 13,869 | 99,995 | 20,990 | 07/15/22 |
Hasnain Faheem | President & CEO President & CEO | Jul 15 | Buy | 7.21 | 138,696 | 999,998 | 3,617,325 | 07/15/22 |
Aranda Richard | Chief Medical Office.. Chief Medical Officer | Jun 22 | Sell | 6.88 | 1,778 | 12,233 | 209,897 | 06/23/22 |
Carter Laura | Chief Scientific Off.. Chief Scientific Officer | May 04 | Sell | 7.20 | 1,262 | 9,086 | 89,042 | 05/05/22 |
Christian Waage | EVP, Tech Ops and Ad.. EVP, Tech Ops and Admin | Mar 23 | Sell | 8.915 | 10,722 | 95,587 | 579,008 | 03/24/22 |
Hasnain Faheem | President & CEO President & CEO | Mar 23 | Sell | 8.915 | 19,035 | 169,697 | 143,465 | 03/24/22 |
Giraudo Bryan | COO/CFO COO/CFO | Mar 23 | Sell | 8.915 | 10,722 | 95,587 | 99,167 | 03/24/22 |
Carter Laura | Chief Scientific Off.. Chief Scientific Officer | Mar 16 | Sell | 8.278 | 5,002 | 41,407 | 90,304 | 03/17/22 |